Stock A066700 THERAGEN ETEX CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Theragen Etex Co.,Ltd.

Equities

A066700

KR7066700006

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 04/06/2024 am IST 		5-day change 1st Jan Change
3,890 KRW 0.00% Intraday chart for Theragen Etex Co.,Ltd. -0.38% -12.98%
2023 MedPacto, Inc. announced that it has received KRW 10.85806127 billion in funding from Theragen Etex Co.,Ltd. CI
2023 MedPacto, Inc. announced that it expects to receive KRW 11.95668467 billion in funding from Theragen Etex Co.,Ltd. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,16,639 2,56,100 3,30,635 2,05,154 1,41,464 1,43,064
Enterprise Value (EV) 1 3,44,459 2,92,037 3,52,787 2,28,295 1,51,265 1,56,080
P/E ratio -30.8 x 5.97 x -36.2 x -17.3 x 14.8 x 5.46 x
Yield - - - - - -
Capitalization / Revenue 2.7 x 1.85 x 2.31 x 1.23 x 0.73 x 0.65 x
EV / Revenue 2.93 x 2.11 x 2.47 x 1.37 x 0.78 x 0.7 x
EV / EBITDA -243 x 38.9 x -125 x -95.7 x 9.78 x 8.82 x
EV / FCF -30.5 x -33 x 30.7 x 36.4 x 77.3 x 40.4 x
FCF Yield -3.28% -3.03% 3.26% 2.75% 1.29% 2.47%
Price to Book 3.91 x 1.89 x 0.88 x 0.92 x 0.99 x 1.05 x
Nbr of stocks (in thousands) 30,446 30,561 31,945 32,005 32,005 32,005
Reference price 2 10,400 8,380 10,350 6,410 4,420 4,470
Announcement Date 19/03/19 18/03/20 23/03/21 23/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,17,475 1,38,083 1,43,023 1,66,567 1,93,379 2,21,725
EBITDA 1 -1,415 7,516 -2,812 -2,387 15,469 17,693
EBIT 1 -4,529 3,396 -7,467 -7,427 10,377 11,849
Operating Margin -3.86% 2.46% -5.22% -4.46% 5.37% 5.34%
Earnings before Tax (EBT) 1 -8,847 56,001 -8,340 -12,676 12,379 33,023
Net income 1 -10,218 43,646 -8,968 -11,854 9,561 26,211
Net margin -8.7% 31.61% -6.27% -7.12% 4.94% 11.82%
EPS 2 -337.3 1,404 -285.6 -371.0 298.7 819.0
Free Cash Flow 1 -11,289 -8,839 11,489 6,272 1,958 3,863
FCF margin -9.61% -6.4% 8.03% 3.77% 1.01% 1.74%
FCF Conversion (EBITDA) - - - - 12.66% 21.83%
FCF Conversion (Net income) - - - - 20.48% 14.74%
Dividend per Share - - - - - -
Announcement Date 19/03/19 18/03/20 23/03/21 23/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 27,820 35,937 22,152 23,141 9,801 13,016
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -19.66 x 4.781 x -7.878 x -9.696 x 0.6336 x 0.7357 x
Free Cash Flow 1 -11,289 -8,839 11,489 6,272 1,958 3,863
ROE (net income / shareholders' equity) -10.9% 37.4% -3.43% -3.68% 5.59% 19.3%
ROA (Net income/ Total Assets) -1.77% 1.02% -1.2% -1.05% 2.17% 3.02%
Assets 1 5,77,757 42,78,988 7,45,996 11,29,923 4,39,788 8,66,637
Book Value Per Share 2 2,658 4,446 11,711 6,958 4,487 4,240
Cash Flow per Share 2 487.0 324.0 448.0 381.0 572.0 679.0
Capex 1 4,034 4,636 3,012 2,749 4,193 4,797
Capex / Sales 3.43% 3.36% 2.11% 1.65% 2.17% 2.16%
Announcement Date 19/03/19 18/03/20 23/03/21 23/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
THERAGEN ETEX CO.,LTD. Stock Theragen Etex Co.,Ltd.
-12.98% 9.08Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.06% 75TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 60TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.52% 36TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.61% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+4.37% 28TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 24TCr
NOVARTIS AG Stock Novartis AG
+9.26% 21TCr
ROCHE HOLDING AG Stock Roche Holding AG
-4.21% 21TCr
PFIZER, INC. Stock Pfizer, Inc.
+2.55% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A066700 Stock
  4. Financials Theragen Etex Co.,Ltd.